Literature DB >> 23085599

Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond.

Stanley R Riddell1, Michael C Jensen, Carl H June.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23085599      PMCID： PMC3654529          DOI： 10.1016/j.bbmt.2012.10.021

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  42 in total

1.  Treatment of advanced leukemia in mice with mRNA engineered T cells.

Authors:  David M Barrett; Yangbing Zhao; Xiaojun Liu; Shuguang Jiang; Carmine Carpenito; Michael Kalos; Richard G Carroll; Carl H June; Stephan A Grupp
Journal:  Hum Gene Ther       Date:  2011-09-23       Impact factor: 5.695

2.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.

Authors:  Naomi N Hunder; Herschel Wallen; Jianhong Cao; Deborah W Hendricks; John Z Reilly; Rebecca Rodmyre; Achim Jungbluth; Sacha Gnjatic; John A Thompson; Cassian Yee
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

Review 3.  Adoptive immunotherapy for cancer: harnessing the T cell response.

Authors:  Nicholas P Restifo; Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

4.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Authors:  Renier J Brentjens; Isabelle Rivière; Jae H Park; Marco L Davila; Xiuyan Wang; Jolanta Stefanski; Clare Taylor; Raymond Yeh; Shirley Bartido; Oriana Borquez-Ojeda; Malgorzata Olszewska; Yvette Bernal; Hollie Pegram; Mark Przybylowski; Daniel Hollyman; Yelena Usachenko; Domenick Pirraglia; James Hosey; Elmer Santos; Elizabeth Halton; Peter Maslak; David Scheinberg; Joseph Jurcic; Mark Heaney; Glenn Heller; Mark Frattini; Michel Sadelain
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Authors:  Hollie J Pegram; James C Lee; Erik G Hayman; Gavin H Imperato; Thomas F Tedder; Michel Sadelain; Renier J Brentjens
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

7.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

8.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.

Authors:  Carolina Berger; Michael C Jensen; Peter M Lansdorp; Mike Gough; Carole Elliott; Stanley R Riddell
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

9.  Tet-On binary systems for tissue-specific and inducible transgene expression.

Authors:  Daniel R Buchholz
Journal:  Methods Mol Biol       Date:  2012

10.  A human memory T cell subset with stem cell-like properties.

Authors:  Luca Gattinoni; Enrico Lugli; Yun Ji; Zoltan Pos; Chrystal M Paulos; Máire F Quigley; Jorge R Almeida; Emma Gostick; Zhiya Yu; Carmine Carpenito; Ena Wang; Daniel C Douek; David A Price; Carl H June; Francesco M Marincola; Mario Roederer; Nicholas P Restifo
Journal:  Nat Med       Date:  2011-09-18       Impact factor: 53.440
View more
  12 in total

Review 1.  Immunotherapeutic approaches to treat multiple myeloma.

Authors:  Mieke W H Roeven; Willemijn Hobo; Nicolaas Schaap; Harry Dolstra
Journal:  Hum Vaccin Immunother       Date:  2013-12-11       Impact factor: 3.452

Review 2.  Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR.

Authors:  Miguel-Angel Perales; Partow Kebriaei; Leslie S Kean; Michel Sadelain
Journal:  Biol Blood Marrow Transplant       Date:  2017-10-13       Impact factor: 5.742

Review 3.  Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.

Authors:  Juanjuan Zhao; Meirong Wu; Zhifeng Li; Sheng Su; Yin Wen; Litian Zhang; Yuhua Li
Journal:  Ann Hematol       Date:  2020-05-09       Impact factor: 3.673

4.  "Cell biology meets physiology: functional organization of vertebrate plasma membranes"--the immunological synapse.

Authors:  Silvia Curado; Sudha Kumari; Michael L Dustin
Journal:  Curr Top Membr       Date:  2013       Impact factor: 3.049

5.  Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L.

Authors:  C Marcela Díaz-Montero; Abdel-Aziz Zidan; Maria F Pallin; Vasileios Anagnostopoulos; Mohamed L Salem; Eric Wieder; Krishna Komanduri; Alberto J Montero; Mathias G Lichtenheld
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 6.  CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas.

Authors:  Katherine A Murphy; Thomas S Griffith
Journal:  Cancers (Basel)       Date:  2016-07-27       Impact factor: 6.639

Review 7.  "Model t" cells: a time-tested vehicle for gene therapy.

Authors:  Sid P Kerkar
Journal:  Front Immunol       Date:  2013-09-27       Impact factor: 7.561

8.  Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells.

Authors:  Rosa Bacchetta; Barbarella Lucarelli; Claudia Sartirana; Silvia Gregori; Maria T Lupo Stanghellini; Patrick Miqueu; Stefan Tomiuk; Maria Hernandez-Fuentes; Monica E Gianolini; Raffaella Greco; Massimo Bernardi; Elisabetta Zappone; Silvano Rossini; Uwe Janssen; Alessandro Ambrosi; Monica Salomoni; Jacopo Peccatori; Fabio Ciceri; Maria-Grazia Roncarolo
Journal:  Front Immunol       Date:  2014-01-31       Impact factor: 7.561

9.  Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity.

Authors:  W K Chan; D Suwannasaen; R E Throm; Y Li; P W Eldridge; J Houston; J T Gray; C-H Pui; W Leung
Journal:  Leukemia       Date:  2014-06-03       Impact factor: 11.528

10.  Cancer immunotherapy: are we there yet?

Authors:  Zihai Li; Lieping Chen; Mark P Rubinstein
Journal:  Exp Hematol Oncol       Date:  2013-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.